Jacob White is a journalist whose work has appeared in publications such as FantasyPros and Gridiron Experts. He specializes in covering news and developments in the biopharmaceutical industry, including mergers and acquisitions, manufacturing updates, and partnering news. Jacob provides in-depth analysis and reporting on the latest happenings in the pharmaceutical world.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Jacob White's articles primarily focus on press releases and private sector announcements related to the healthcare and pharmaceutical industry, with an emphasis on mergers and acquisitions. He frequently covers news about specific companies in the pharmaceutical industry, including their partnerships, manufacturing updates, and supplier relationships.
Given this focus, Jacob is likely to be interested in receiving pitches related to breaking news about mergers and acquisitions within the pharmaceutical industry or significant partnerships between major healthcare companies. Additionally, he may be open to receiving information about new developments from key suppliers or manufacturers within the sector.
Pitches should provide concise details of how a particular announcement or development contributes to broader trends within the healthcare and pharmaceutical landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jacob White
Roche has agreed to acquire Poseida Therapeutics, a San Diego, California-based clinical-stage cell- and gene-therapy company developing treatments for cancer, autoimmune and rare diseases, in a $1.5-billion deal ($1.0 billion in closing and $500 million in potential milestones).
Amgen has announced a $1-billion expansion to establish a second drug substance manufacturing facility in Holly Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment. In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting a robust biomanufacturing hub.
Supplier News: Resilience, Cambrex, Agilent & More The latest from CDMOs, CMOs, and suppliers featuring Resilience, Sartorius, Agilent, Cambrex, Evotec, Hovione and Samabriva.
Global Briefs: Novo Nordisk, Coherus & More A roundup of news from Novo Nordisk, Novavax, Coherus BioSciences and Intas Pharmaceuticals. Highlights below.
By: Jacob White
AbbVie has completed its $1.4-billion acquisition of Aliada Therapeutics, a bio/pharmaceutical company focused on central nervous system (CNS) diseases, for $1.4 billion. The companies had
By: Jacob White
Eli Lilly and Company has announced a $3-billion expansion of its sterile manufacturing facility in Pleasant Prairie, Wisconsin. Lilly had acquired the facility earlier this year (2024) from Nexus Pharmaceuticals, a Lincolnshire, Illinois-based specialty- and generic-drug manufacturer of injectable drugs.
Partnering News: Gilead, Takeda & More A roundup of bio/pharmaceutical partnering news from Gilead/Tubulis and Takeda/Keros.
Supplier News: SK pharmteco The latest from CDMOs, CMOs, and suppliers featuring SK pharmteco. General
Mfg News: Daiichi Sankyo & BioMarin A roundup of manufacturing news from Daiichi Sankyo and BioMarin Pharmaceutical. Highlights below.
By: Jacob White
Novo Holdings, the parent company of Novo Nordisk, has completed its acquisition of Catalent for $16.5 billion. The deal was announced in February 2024.
(833) 317-6278 
